The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.
👤 Zhang, Chi
👤 Wu, Zhao
👤 Li, Jia-Wen
👤 Zhao, Hong
👤 Wang, Gui-Qiang
⏰ 2020
📚 Int J Antimicrob Agents
CoV Index